To The Main Page
About RTC Our Projects Stem Cell Therapy Research Translation Service/Technology Transfer Contact
Regulatory
Good Laboratory Practise
Good Clinical Practise
Good Vigilance Practise
Good Manufacturing Practise
Exploitation/PR
Reimbursement
Network and Publications
 

Reimbursement

The EU reimbursement proceduresare not harmonized. They depend on the social legislation of each single member state. In Germany, the “Sozialgesetzbuch V” (SGB V) is authoritative for the corresponding procedure. So far, a general reimbursement for the ATMPs by the compulsory health insurance does not exist.

In our Clinic for Heart Surgery  the treatment method with stem cells for heart diseases has been classified as innovative therapy according to the DRG („Diagnosis Related Groups“)-Hospital Remuneration system into the group F96Z ( Stem cell transfusion and circulatory disturbance). For this treatment a case-based lump sum will be reimbursed by the health insurance. For this purpose, an individual application for each patient has to be filed to the corresponding health assurance. This implies that our patients can benefit from the stem cell therapy already now.

 

 

 

Legal The RTC is supported by the BMBF and the State Mecklenburg-Western Pomerania using EU Structural Funds.